Nursing site allnurses has published an extensive article about the potential perioperative dangers facing patients who take GLP-1 drugs.
The article, “Why GLP-1 Receptor Agonists Force Aborted Surgeries and Airway Crises Under Anesthesia,” begins with a lengthy patient scenario that brings those potential dangers home.
“This emergency plays out daily across hospital operating rooms, endoscopy suites, and ambulatory surgical centers nationwide,” states the article. The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), exposes an operational blind spot in perioperative care. The traditional nil per os (NPO) rule assumes normal human gastric physiology. GLP-1 receptor agonists directly arrest that physiology.”
The article adds that “delayed gastric emptying from GLP-1 drugs causes undigested food to linger past standard fasting windows, triggering emergency airway intubations and canceled surgeries. Aborted cases create severe financial and operational fallout across patients, nurses, surgeons, and hospitals. Facilities must modernize intake questionnaires and enforce 24-hour clear liquid protocols.”
The article then delves into adjustments that perioperative providers and facilities should make to account for patients who take GLP-1s. Read the full article here.
